It will be sold as Spravato. More specifically, it’s for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant. “There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” Dr. Tiffany Farchione, acting director of the… Read More »
Memory loss does not only occur in neurodegenerative diseases, such as dementia. It also happens with age, or in relation to mental health problems, such as depression. Now, researchers have developed new compounds that could reverse this cognitive effect. Newly developed compounds may offer fresh hope for depression-related memory loss. Memory loss is not solely… Read More »
While we have considerable data on the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, most of this research focuses on the risk of congenital malformations in exposed children. We have far less information regarding the long-term effects of SSRI antidepressants on neurodevelopmental outcomes in exposed children. A recent study looks at executive functioning… Read More »
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics has conducted three randomized controlled trials, enrolling a total of 247 women diagnosed… Read More »